Signos raises $20M to revolutionize metabolic health with AI and CGM tech
Signos, a San Francisco-based metabolic health platform, has secured $20 million in Series B funding. The company, founded in 2018 by Dr. Peter Attia, combines AI technology with continuous glucose monitoring (CGM) to provide real-time health insights. Investors include major firms like Cheyenne Ventures and GV (Google Ventures).
The latest funding round was led by Cheyenne Ventures, a venture capital firm specializing in technology, healthcare, and consumer products. GV, the investment arm of Alphabet Inc., also contributed, alongside Dexcom Ventures and Samsung. These funds will support Signos in expanding its team, enhancing its platform, and advancing metabolic health research.
The $20 million investment will help Signos scale its operations and refine its technology. With backing from prominent venture firms, the company aims to broaden its impact in metabolic health. Further research and platform improvements are expected in the coming months.
